Chemokine CXC ligand 16 and TNF- receptors 1 & 2 as Novel Markers in Egyptian Diabetic Subjects with and without Renal DiseaseHala Fawzy Ahmed Hekal

Abstract

Diabetic nephropathy (DN) is one of the major microvascular complications of diabetes. DN is a leading cause of morbidity and mortality, and it invariably leads to an end-stage renal disease (ESRD). The prevalence of DN has tremendously increased with the relentless rise in the incidence of diabetes over the last couple decades. The reliability of current tests in predicting the onset, progression and response to various regimens for diabetic nephropathy is still under debate; and it has engendered a search for more sensitive and specific biomarkers. We aimed to evaluate the role of some relevant biomarkers in the pathogenesis of DN and that potentially may be used to predict the onset and/or monitor the progression of nephropathy. Methods: Seventy Egyptian subjects, including patients with diabetic nephropathy (DN group), type 2 diabetes mellitus (T2DM group), and healthy controls of similar age and gender (control group), were enrolled in this study. Serum levels of CXC Chemokine Ligand 16 (CXCL16) and tumor necrosis factor- receptors 1 & 2 (TNFR1 & TNFR2) were measured using ELISA technique. The levels of Lipid profile including (TAG, TC, HDL-c, LDL-c and VLDLc), kidney function tests including (Creatinine, eGFR, BUN, uric acid, Urinary P/C Ratio), CRP, fasting blood glucose (FBG) and HbA1c were also analyzed.